High dose frusemide in acute renal failure: a controlled trial

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• Acute renal failure (ARF) following trauma or surgery presents a significant clinical challenge.
• Oliguria is a common and concerning symptom in ARF.
• Diuretic therapy is frequently employed in managing ARF, but optimal dosing strategies remain debated.

Purpose of the Study:

• To compare the efficacy of a sustained high-dose frusemide regimen versus a single injection in patients with established ARF.
• To evaluate the impact of different frusemide administration protocols on urine output and renal recovery.

Main Methods:

• A prospective, randomized study involving 58 patients with ARF post-trauma or surgery.
• Control group received a single 1g frusemide injection over 4 hours.
• Test group received sustained frusemide (3g/24hr, IV or oral) until urine output goal or creatinine normalization.

Main Results:

• Sustained frusemide reversed or prevented oliguria in 24 of 28 patients, compared to only 2 of 28 in the control group.
• No significant differences were observed in the number of dialyses, duration of renal failure, or mortality between the groups.
• Two patients experienced deafness, one permanently, as a serious complication.

Conclusions:

• Sustained high-dose frusemide is effective in restoring urine output in ARF.
• While improving oliguria, this regimen did not alter key clinical outcomes like dialysis requirements or mortality.
• The potential risk of ototoxicity necessitates careful consideration of frusemide dosing in ARF.